No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Climb Bio to Be Added to the Nasdaq Biotechnology Index
Leerink Partners Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $10
Express News | Climb Bio Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $10
Eliem Therapeutics GAAP EPS of -$0.13
Climb Bio Inc. Shifts Focus to Immune-Mediated Diseases
Climb Bio Q3 EPS $(0.13) Up From $(0.15) YoY